We are live on
!
Find out more
State Street SPDR S&P Pharmaceuticals ETF
XPH
XPH
65 hedge funds and large institutions have $98.6M invested in State Street SPDR S&P Pharmaceuticals ETF in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
10% more funds holding
Funds holding: 59 → 65 (+6)
2.58% less ownership
Funds ownership: 52.68% → 50.1% (-2.6%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
15% less capital invested
Capital invested by funds: $117M → $98.6M (-$18M)
84% less call options, than puts
Call options by funds: $250K | Put options by funds: $1.54M
Holders
65
Holders Change
+6
Holders Change %
+10.17%
% of All Funds
1.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
14
Reduced
16
Closed
7
Calls
$250K
Puts
$1.54M
Net Calls
-$1.29M
Net Calls Change
-$58K
Top Buyers
Top Sellers
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$16.9M |
| 2 |
Morgan Stanley
New York
|
-$2.77M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$2.05M |
| 4 |
Jane Street
New York
|
-$887K |
| 5 |
CI
CX Institutional
Auburn,
Indiana
|
-$824K |
